Mitesco (MITI) 10-K 2 May 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Apr. 29, 2016	Jun. 30, 2015
Document And Entity Information
Entity Registrant Name	True Nature Holding, Inc.
Entity Central Index Key	802,257
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer	No
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 851,948
Entity Common Stock, Shares Outstanding		12,385,000
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,015

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash	$ 28,185
Prepaid expenses - related party	$ 17,000
Assets of discontinued operations		$ 157,630
Total current assets	$ 45,185	157,630
Assets of discontinued operations		807,017
TOTAL ASSETS	$ 45,185	$ 964,647
Current liabilities
Accounts payable	414,463
Accrued interest	14,918	$ 2,071
Accrued liabilities	13,325
Debentures payable	$ 122,167	$ 122,167
Liabilities of discontinued operations		3,104,855
Total current liabilities	$ 564,873	3,229,093
TOTAL LIABILITIES	$ 564,873	$ 3,229,093
Commitments and Contingencies (Note 11)
STOCKHOLDERS' DEFICIT
Preferred stock, $0.01 par value - 10,000,000 shares authorized, none issued and outstanding as of December 31, 2015; $0.0001 par value - 50,000,000 shares authorized, none issued and outstanding as of December 31, 2014
Common stock, $0.01 par value - 500,000,000 shares authorized, 11,765,000 shares issued and outstanding at December 31, 2015; $0.0101 par value - 1,980,198 shares authorized, 542,605 shares issued and outstanding at December 31, 2014	$ 117,650	$ 5,480
Additional paid-in capital	$ 3,917	14,220,267
Accumulated Other comprehensive loss		17,974
Accumulated deficit	$ (641,255)	(16,508,167)
Total Stockholders' Deficit	(519,688)	(2,264,446)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 45,185	$ 964,647

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock par value	$ 0.01	$ 0.0001
Preferred stock shares authorized	10,000,000	50,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock par value	$ 0.01	$ 0.0101
Common stock shares authorized	500,000,000	1,980,198
Common stock shares issued	11,765,000	542,605
Common stock shares outstanding	11,765,000	542,605

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Net Sales
Cost of sales
Gross Profit
Operating expenses:
Research and development
Selling, general and administrative	$ 64,756
Total operating expenses	64,756
Operating Loss from Continuing Operations	(64,756)
Interest expense, net	(896)
Loss From Continuing Operations before Income Taxes	$ (65,652)
Provision for income taxes
Net Loss From Continuing Operations	$ (65,652)
Discontinued Operations (Note 4):
Net Loss from discontinued operations, net of tax	(337,362)	$ (3,770,144)
Other comprehensive gain, net of tax	24,815	14,325
Comprehensive Loss from Discontinued Operations	(312,547)	(3,755,819)
Net Loss	(403,014)	(3,770,144)
Comprehensive Net Loss	$ (378,199)	$ (3,755,819)
Net Loss from Continuing Operations Per Share - Basic and Diluted	$ (0.11)
Net Loss from Discontinued Operations Per Share - Basic and Diluted	(0.55)	$ (7.56)
Net Loss Per Share - Basic and Diluted	$ (0.66)	$ (7.56)
Weighted Average Number of Shares Outstanding During the Period - Basic and Diluted	612,053	498,723

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Preferred Stock	Common Stock	Additional Paid-in Capital (Deficit)	Accumulated Comprehensive Loss	Accumulated Deficit	Total
Balance beginning at Dec. 31, 2013		$ 4,670	$ 12,396,356	$ 3,649	$ (12,738,023)	$ (333,348)
Balance beginning, Shares at Dec. 31, 2013		462,355
Sale of common stock, net of issuance costs		$ 396	663,314			$ 663,710
Sale of common stock, net of issuance costs, Shares		39,235
Exchange of Trunity Holdings, Inc. preferred stock for True Nature Holding, Inc. common stock
Debt beneficial conversion feature for shares and warrants			189,687			$ 189,687
Common stock issued upon conversion of note payable, net of issuance costs		$ 50	94,940			$ 94,990
Common stock issued upon conversion of note payable, net of issuance costs, Shares		5,000
Common stock issued upon conversion of debenture prior to Spin-Out
Discount related to issuance of debt with warrants and allocated fair value to beneficial conversion feature prior to Spin-Out
Stock compensation expense - discontinued operations
Gain on extinguishment of debt - discontinued operations
Foreign currency translation gain - discontinued operations
Common stock issued for satisfaction of payables
Common stock issued to Spin-Out Company, Trunity Inc.
Shares issued and adjustments related to reverse split
Shares issued for services		$ 350	69,650			$ 70,000
Shares issued for services, Shares		34,654
Warrants issued for services			20,752			20,752
Common stock issued for convertible note payable		$ 14	24,736			$ 24,750
Common stock issued for convertible note payable, Shares		1,361
Spin-out adjustment
Stock compensation period costs			450,736			$ 450,736
Loss on debt extinguishment			$ 310,096			310,096
Foreign currency translation gain				$ 14,325		14,325
Net loss					$ (3,770,144)	(3,770,144)
Balance ending at Dec. 31, 2014		$ 5,480	$ 14,220,267	$ 17,974	$ (16,508,167)	$ (2,264,446)
Balance ending, Shares at Dec. 31, 2014		542,605				542,605
Issuance of Trunity Holdings, Inc. preferred stock for acquisition of Newco4pharmacy, LLC			106,900			$ 106,900
Issuance of Trunity Holdings, Inc. preferred stock for acquisition of Newco4pharmacy, LLC, Shares	1,000
Exchange of Trunity Holdings, Inc. preferred stock for True Nature Holding, Inc. common stock		$ 100,000	(100,000)
Exchange of Trunity Holdings, Inc. preferred stock for True Nature Holding, Inc. common stock, Shares	(1,000)	10,000,000
Common stock issued upon conversion of debenture prior to Spin-Out		$ 883	141,631			$ 142,514
Common stock issued upon conversion of debenture prior to Spin-Out, Shares		87,383
Discount related to issuance of debt with warrants and allocated fair value to beneficial conversion feature prior to Spin-Out			274,122			274,122
Discount related to issuance of debt with warrants and allocated fair value to beneficial conversion feature prior to Spin-Out, Shares
Stock compensation expense - discontinued operations			151,708			151,708
Gain on extinguishment of debt - discontinued operations			$ (1,867,428)			(1,867,428)
Foreign currency translation gain - discontinued operations				$ 24,815		$ 24,815
Common stock issued for conversion of debt		$ 7,421	$ (7,421)
Common stock issued for conversion of debt, Shares		742,098
Common stock issued for satisfaction of payables		$ 1,893	(1,893)
Common stock issued for satisfaction of payables, Shares		189,305
Common stock issued to Spin-Out Company, Trunity Inc.		$ 2,033	(2,033)
Common stock issued to Spin-Out Company, Trunity Inc., Shares		203,293
Shares issued and adjustments related to reverse split		$ (60)	$ 60
Shares issued and adjustments related to reverse split, Shares		316
Net loss from discontinued operations, net of tax					$ (337,362)	$ (337,362)
Spin-out adjustment			$ (12,915,913)	$ (42,789)	$ 16,269,926	3,311,224
Stock compensation period costs			$ 3,917			3,917
Net loss					$ (65,652)	(403,014)
Balance ending at Dec. 31, 2015		$ 117,650	$ 3,917		$ (641,255)	$ (519,688)
Balance ending, Shares at Dec. 31, 2015		11,765,000				11,765,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash Flows from Operating Activities:
Net Loss	$ (403,014)	$ (3,770,144)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss from discontinued operations	337,362	$ 3,770,144
Stock-based compensation	3,917
Prepaid expenses	(17,000)
Changes in operating assets and liabilities:
Accounts payable	(4,316)
Accrued interest and other liabilities	4,336
Net Cash Used in Operating Activities	(78,715)
Cash Flows from Financing Activities:
Proceeds received from issuance of preferred stock resulting from transaction with Newco4pharmacy	106,900
Net Cash Used in Financing Activities	106,900
Discontinued Operations:
Operating activities	(287,725)	$ (1,444,075)
Investing activities	(108,812)	(591,481)
Financing activities	398,838	1,237,611
Net Increase (Decrease) in Cash and Cash Equivalents for Discontinued Operations	2,301	$ (797,945)
Net Increase in Cash and Cash Equivalents for Continuing Operations	28,185
Cash, Beginning of Year	14,119	$ 812,064
Cash to Spin-Out	(16,420)
Cash, End of Year	28,185	$ 14,119
Non-cash Transactions:
Exchange of Trunity Holdings, Inc. preferred stock for True Nature Holding, Inc. common stock	100,000
Common stock issued upon conversion of debenture prior to spin-out	142,514
Discount related to issuance of debt with warrants and allocated fair value to beneficial conversion feature prior to spin-out	274,122
Stock compensation expense- discontinued operations	151,708
Gain on extinguishment of debt - discontinued operations	(1,867,428)
Foreign currency translation gain - discontinued operations	24,815
Common stock issued for conversion of debt- discontinued operations	7,421	$ 100,000
Common stock issued for satisfaction of payables	1,893
Common stock issued to spin-out company, Trunity, Inc.	2,033
Shares issued and adjustments related to reverse split	60
Spin out adjustment	16,269,926
Trunity Holdings, Inc. liabilities assumed by True Nature Holding, Inc. after spin out.	$ 441,511
Discount cost related to issuance of debentures, warrants and convertible notes		$ 499,784
Supplemental Disclosure of Cash Flow Information:
Cash paid during the year for interest		$ 9,603

Note 1 - Organization, Basis of

Note 1 - Organization, Basis of Presentation and Nature of Operations	12 Months Ended
	Dec. 31, 2015
Note 1 - Organization Basis Of Presentation And Nature Of Operations
Note 1 - Organization, Basis of Presentation and Nature of Operations	Note 1 – Organization, Basis of Presentation and Nature of Operations True Nature Holding, Inc. (the “Company”), previously known as Trunity Holdings, Inc., became a publicly-traded company through a reverse merger with Brain Tree International, Inc., a Utah corporation (“BTI”). BTI was incorporated on July 26, 1983 to specialize in the development of high technology products or applications including, but not limited to, electronics, computerized technology, new technological product fields, and precious metals. Trunity Holdings, Inc. was the parent company of the prior educational business, named Trunity, Inc., which was formed on July 28, 2009 through the acquisition of certain intellectual property by its three founders. True Nature Holding, Inc. is a Corporation organized under the Laws of Delaware with principal offices located in Atlanta, Georgia. On December 9, 2015, the company announced a series of steps aimed at restructuring the business. In the first step, the Company entered into a Securities Exchange Agreement (the “Agreement”) with Newco4pharmacy, LLC (“N4P”), a Georgia limited liability company that was formed on November 6, 2015 for the purpose of executing a business plan for the acquisition and integration of a network of compounding pharmacy businesses. Pursuant to the terms of the Agreement, the company acquired 100% of the membership interests of N4P, certain assets and the business plan of N4P, including a letter of intent for a potential acquisition in exchange for newly authorized Series X preferred stock, which subsequently converted into 10,000,000 shares of common stock. Additional steps in the restructuring included a) a conversion of existing debt into equity, b) a spin out of the legacy educational business into a newly formed private company with the ownership pro-rata with the ownership of Trunity as of December 18, 2015, c) a change in the equity structure that included a reverse split of 1 for 101, such that all holders of 101 shares of common stock would then have 1 share, d) modifications to the Articles of Incorporation such that the Company now has 500,000,000 shares of common stock authorized and 100,000,000 of preferred stock authorized, and e) a change in the name of Trunity Holdings, Inc. to True Nature Holding, Inc. (there was no change in the stock symbol “TNTY”). On December 31, 2015 the Company completed the restructuring and spin-out of educational business. Following the spin-out, as of December 31, 2015 the Company had 11,765,000 shares outstanding, with 10,000,000 held by the former members of N4P, and 1,765,000 held by the legacy shareholders of the Company, including those who converted their debts into equity. Further, all the shareholders of record date as of December 18, 2015, received shares in the newly formed entity, Trunity, Inc. (“Spin-Out”), a Florida corporation, pro-rated to their ownership percentage as of that date. The former members of N4P did not participate in the allocation of shares in the spin out company. The Company intends to acquire a series of businesses which specialize in compounding pharmacy activities, largely direct to consumers, doctors and veterinary professionals. The accompanying consolidated financial statements include the accounts of True Nature Holding, Inc. as December 31, 2015. The accompanying consolidated financial statements include the accounts and Trunity Holdings, Inc. and its wholly-owned subsidiary Trunity, Inc., for the year ended December 31, 2014 and for the time period in fiscal 2015 up to the spin-out of Trunity, Inc. Refer to Note 4 regarding more information regarding the Spin-Out and related discontinued operations classification. All intercompany accounts have been eliminated in the consolidation.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Note 2 - Summary Of Significant Accounting Policies
Note 2 - Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Accounting Use of Estimates - Comprehensive Loss – Cash - Revenue Recognition- Stock-Based Compensation- Equity instruments issued to other than employees are recorded on the basis of the fair value of the instruments. In general, the measurement date is when either a (a) performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant. Convertible Instruments Common Stock Purchase Warrants- Stockholders’ Equity- Per Share Data- The Company has excluded all common equivalent shares outstanding for warrants, options and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of December 31, 2015, the Company had 78,462 warrants, 67,879 options, 6,922 potential shares which may be issued resulting from the provisions of convertible notes, respectively. As of December 31, 2014, the Company had 171,369 warrants, 67,434 options, 168,869 potential shares which may be issued resulting from the provisions of convertible notes, respectively. Income Taxes- Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has determined that a valuation allowance is needed due to recent taxable net operating losses, the sale of profitable divisions and the limited taxable income in the carry back periods. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and certain tax loss carryforwards, less any valuation allowance. The Company accounts for uncertain tax positions as required in that a position taken or expected to be taken in a tax return is recognized in the consolidated financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company does not have any material unrecognized tax benefits. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as components of interest expense and other expense, respectively, in arriving at pretax income or loss. The Company does not have any interest and penalties accrued. The Company is generally no longer subject to U.S. federal, state, and local income tax examinations for the years before 2012. Business Combinations- ● future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and ● discount rates utilized in valuation estimates. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate. Impairment of Long-Lived Assets- Financial Instruments and Fair Values- Level 1 – inputs include exchange quoted prices for identical instruments and are the most observable. Level 2 – inputs include brokered and/or quoted prices for similar assets and observable inputs such as interest rates. Level 3 – inputs include data not observable in the market and reflect management judgment about the assumptions market participants would use in pricing the asset or liability. The use of observable and unobservable inputs and their significant in measuring fair value are reflected in our hierarchy assessment. The carrying amount of cash, prepaid assets, accounts payable and accrued liabilities approximates fair value due to the short-term maturities of these instruments. Because cash and cash equivalents are readily liquidated, management classifies these values as Level 1. The fair value of the debentures, approximate their book value as the instruments are short-term in nature and contain market rates of interest. Because there is no ready market or observable transactions, management classifies the debentures as Level 3. Recently Issued Accounting Standards- In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, which relates to the financial statement presentation of debt issuance costs. This guidance requires debt issuance costs to be presented in the balance sheet as a reduction of the related debt liability rather than an asset. The guidance is effective for annual and interim periods beginning after December 15, 2015 and early adoption is permitted and will only result in a change in presentation of the costs on the balance sheet. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes. The guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. The guidance becomes effective for annual reporting periods beginning after December 15, 2016 with early adoption permitted. The adoption of this guidance will only result in a change in the presentation of deferred taxes on the balance sheet.

Note 3 - Newco4pharmacy Transac

Note 3 - Newco4pharmacy Transaction	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Note 3 - Newco4pharmacy Transaction	Note 3 – Newco4pharmacy Transaction On December 9, 2015, Trunity Holdings, Inc. acquired 100% of the membership interests of Newco4pharmacy, LLC. The consideration paid was the issuance of a newly created Series X Preferred stock which was exchanged on December 31, 2015 for 10,000,000 shares of the Company’s common stock. The $106,900 fair value of the preferred stock issued and common stock exchanged approximated the fair value of the assets acquired from Newco4pharmacy, LLC which consisted of cash. Acquisition costs were nominal pertaining to the transaction.

Note 4 - Spin-Out and Discontin

Note 4 - Spin-Out and Discontinued Operations	12 Months Ended
	Dec. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Note 4 - Spin-Out and Discontinued Operations	Note 4 – Spin-Out and Discontinued Operations On December 31, 2015, the Company completed the restructuring and spin-out of software educational business, resulting in True Nature Holding, Inc. becoming purely focused on acquiring a series of businesses which specialize in compounding pharmacy activities, largely direct to consumers, doctors and veterinary professionals. The results of the operations associated with the Spin-Out company and Trunity Holdings, Inc., qualifies as discontinued operations. The results of operations associated with discontinued operations were as follows: For the Year Ended December 31, December 31, 2015 2014 Net Sales $ 464,786 $ 227,655 Cost of sales 220,228 172,966 Gross Profit 244,558 54,689 Operating Expenses: Research and development 734,985 892,092 Selling, general and administrative 938,799 2,235,012 Total operating expenses 1,673,784 3,127,104 Operating Loss from Discontinued Operations (1,429,226 ) (3,072,415 ) Other Expense: Interest expense, net (775,564 ) (381,941 ) Disposal on fixed assets — (5,692 ) Gain (Loss) on debt extinguishment 1,867,428 (310,096 ) Net Loss from Discontinued Operations $ (337,362 ) $ (3,770,144 ) Other Comprehensive Gain Net of Tax: Foreign currency translation adjustments 24,815 14,325 Comprehensive Loss from Discontinued Operations $ (312,547 ) $ (3,755,819 ) The following table presents the carrying value of the major categories of assets and liabilities of discontinued operations reflected on the Company’s consolidated balance sheet as of December 31, 2014: 2014 Cash and cash equivalents $ 14,119 Accounts receivable 3,020 Prepaid expenses and other current assets 104,592 Debt issuance costs 35,899 Property and equipment, net 19,716 Capitalized software development costs, net 774,406 Other assets 12,895 ASSETS OF DISCONTINUED OPERATIONS $ 964,647 Accounts payable $ 984,841 Accrued interest and other liabilities 300,297 Debentures carrying value 1,334,996 Convertible note payable 115,463 Deferred revenue 324,169 Convertible promissory notes 45,089 TOTAL LIABILITIES $ 3,104,855

Note 5 - Related Party Transact

Note 5 - Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Note 5 - Related Party Transactions	Note 5 – Related Party Transactions The Company’s Chairman of the Board, CEO and CFO, Stephen Keaveney has a consulting agreement in the amount of $10,000 per month for professional fees. Mr. Keaveney was paid $10,000 in 2015. Mr. William Ross, board member for 2015, purchased 40,000 shares at $0.13 per share in exchange for $5,000 of consideration. A shareholder of the Company has a consulting agreement in the amount of $10,000 per month for professional fees and was paid $27,000 in 2015. $17,000 has been classified as a prepaid asset as of December 31, 2015 in the consolidated balance sheets.

Note 6 - Debt

Note 6 - Debt	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Note 6 - Debt	Note 6 – Debt August 2014 Convertible Debentures (Series C) In fiscal 2015, all debentures issued by Trunity Holdings, Inc. to fund the former educational business were eligible to participate in a debt conversion; however, one debenture holder that was issued a Series C Convertible Debenture (the “Series C Debenture”) in August 2014 with an aggregate face value of $100,000 in exchange for the cancellation of Series B Convertible Debentures with a carrying value of $110,833 did not convert. The Series C Debenture accrues interest at an annual rate of 10%, matured on October 31, 2015, and is convertible into the Company’s common stock at a conversion rate of $20.20 per share. The holders of the Series C Debenture also received warrants to acquire 4,950 shares post-split of common stock for an exercise price of $20.20 per share, exercisable over five years. The former educational business in fiscal 2014 allocated the face value of the Series C Debenture to the warrants and the debentures based on its relative fair values, and allocated to the warrants, which was recorded as a discount against the Series C Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed in fiscal 2014 upon execution of the new debentures and is recorded as debt extinguishment costs within discontinued operations. As of December 31, 2015, the carrying value of this Series C Debenture was $110,833 and accrued interest expense of $13,337. As of December 31, 2014, the carrying value of this Series C Debenture was $110,833 and accrued interest expense of $1,847. November 2014 Convertible Debentures (Series D) In fiscal 2015, all debentures issued by Trunity Holdings, Inc. to fund the former educational business were eligible to participate in a debt conversion however one debenture holder that was issued a Series D Convertible Debenture (the “Series D Debenture”) in November 2014 with an aggregate face value of $10,000 in exchange for the cancellation of Series B Convertible Debenture with a carrying value of $11,334 that did not participate in the debt conversion restructuring. The Series D Debenture accrues interest at an annual rate of 12%, matured on October 31, 2015, and is convertible into the Company’s common stock at a conversion rate of $16.67 per share. The holders of the Series D Debenture also received warrants to acquire 495 shares post-split of common stock for an exercise price of $20.20 per share, exercisable over five years. The former educational business in fiscal 2014 allocated the face value of the Series D Debenture to the warrants and the debentures based on their relative fair values, and allocated to the warrants, which was recorded as a discount against the Series D Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed in fiscal 2014 upon execution of the new debentures and is recorded as debt extinguishment costs within discontinued operations. As of December 31, 2015, the carrying value of the Series D Debenture was $11,334 and accrued interest expense of $1,581. As of December 31, 2014, the carrying value of the Series D Debenture was $11,334 and accrued interest expense of $224.

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Note 7 - Stockholders' Deficit	Note 7 – Stockholders’ Deficit Common Share Issuance - Spin-out Transaction

Note 8 - Stock-Based Compensati

Note 8 - Stock-Based Compensation	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Note 8 - Stock-Based Compensation	Note 8 – Stock-Based Compensation The Company has two Employee, Director and Consultant Stock Option Plans that were not terminated as a result of the fiscal 2015 restructuring of the Company and spin-out and have continued as part of the operations as detailed below. In fiscal 2015, the option pool pertaining to the 2009 Employee, Director and Consultant Stock Option Plan (the “2009 Plan”) was adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan, resulting in an authorized option pool of 18,152. Stock options typically vest over a three-year period and have a life of ten years from the date granted. As of December 31, 2015 there were 3,610 shares available for future awards under this plan. In fiscal 2015, the option pool pertaining to the 2012 Employee, Director and Consultant Stock Option Plan (the “2012 Plan”) was adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan, resulting in an authorized options pool of 74,257. Stock options typically vest over a three year period and have a life of ten years from the date granted. As of December 31, 2015, there were 45,673 shares available for future awards under this plan. In addition, there are approximately 24,753 in options outstanding that were issued to a former CEO of the Company in fiscal 2014. These options issued are outside of the 2009 and 2012 Plans. During the years ended December 31, 2015, the Company granted 1,683 options to acquire shares of common stock to employees, directors or consultants. The grant-date fair value of options is estimated using the Black-Scholes option pricing model. The per share weighted average fair value of stock options granted during the twelve months ended December 30, 2015 was $2.08 and was determined using the following assumptions: expected price volatility ranging between 44.9% to 50.1%, risk-free interest rate ranging from 1.60% to 2.20%, zero expected dividend yield, and six to ten years expected life of options. The expected term of options granted is based on the simplified method in accordance with Securities and Exchange Commission Staff Accounting Bulletin 107, and represents the period of time that options granted are expected to be outstanding. The Company makes assumptions with respect to expected stock price volatility based on the average historical volatility of peers with similar attributes. In addition, the Company determines the risk free rate by selecting the U.S. Treasury with maturities similar to the expected terms of grants, quoted on an investment basis in effect at the time of grant for that business day. As of December 31, 2015, there was approximately $12,550 of total unrecognized stock compensation expense, related to unvested stock options under the Plans. This expense is expected to be recognized over the remaining weighted average vesting periods of the outstanding options of less than one year. The Company recorded $3,917 in stock compensation expense to continuing operations within selling, general and administrative expenses on the consolidated statements of operations and comprehensive loss pertaining to the vesting of options in fiscal 2015. A summary of options issued, exercised and cancelled are as follows: Shares Weighted- Average Exercise Price ($) Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value ($) Outstanding at December 31, 2013 82,336 $ 42,42 9.09 — Granted 13,159 21.21 9.11 — Cancelled (28,061 ) 46.46 — — Outstanding at December 31, 2014 67,434 $ 26.26 8.11 — Granted 1,683 2.08 9.18 — Cancelled (1,238 ) 18.79 — — Outstanding at December 31, 2015 67,879 $ 21.40 7.17 — Exercisable at December 31, 2015 66,270 $ 36.70 6.79 —

Note 9 - Warrants to Purchase C

Note 9 - Warrants to Purchase Common Stock	12 Months Ended
	Dec. 31, 2015
Note 9 - Warrants To Purchase Common Stock
Note 9 - Warrants to Purchase Common Stock	Note 9 – Warrants to Purchase Common Stock Subsequent to the restructuring of the Company and the spin-out, the Company had warrants to purchase common stock outstanding that were not terminated and have continued as part of the operations as detailed below. The warrants were adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan as authorized. During the twelve months ended December 31, 2015, the Company issued, in connection with the restructuring of debentures and private placement offerings for the sale of common stock, warrants to purchase 5,233 shares of the Company’s common stock at exercise prices ranging of $15.15 to $90.90 per share. All warrants outstanding as of December 31, 2015 are scheduled to expire at various dates through 2019. A summary of warrants issued, exercised and expired are as follows: Shares Weighted- Average Exercise Price ($) Weighted-Average Remaining Contractual Term Outstanding at December 31, 2013 103,823 $ 101 1.36 Granted 70,753 29.29 4.41 Expired (3,207 ) 303 — Outstanding at December 31, 2014 171,369 $ 70.70 2.04 Granted 5,233 16.36 2.67 Expired (98,140 ) 100.81 — Outstanding at December 31, 2015 78,462 $ 29.55 3.43 Exercisable at December 31, 2015 78,462 $ 29.55 3.43

Note 10 - Income Taxes

Note 10 - Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Note 10 - Income Taxes	Note 10 – Income Taxes Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for tax purposes plus operating loss carryforwards. The tax effects of significant items comprising the Company’s net deferred tax assets are as follows: As of December 31, 2015 Tax Deferred Asset: Net operating loss carryforward $ 238,784 Deferred Tax Assets $ 238,784 Valuation Allowance (238,784 ) Total Net Deferred Tax Asset $ — As of December 31, 2015, the Company has net deferred tax assets of $629,042 (tax effected $238,784). Due to losses reported and considering the Company’s limited operating history and uncertainty of achieving significant profits to fully realize the deferred tax assets, the Company has recorded a full valuation allowance against the deferred tax assets. The Company has federal operating losses carried forward of $629,042 that can be carried forward for twenty years due to the spin-out and restructuring plan. The operating losses will begin to expire in 2036. The Company’s ability to utilize the net operating losses is contingent on generating sufficient future taxable income prior to their expiration. In 2015, the Company had a change in ownership and name. The prior year annual financial statement showing deferred tax assets of $15.5 million ($6.1 million tax effected) was comprised of the activity of a subsidiary of Trunity Holdings, Inc., Trunity, Inc. Trunity, Inc. underwent a change in ownership when the Newco4pharmacy, LLC merged into Trunity Holdings, Inc. After the merger the subsidiary’s assets, liabilities and operations were part of a spin out to the private company and the deferred tax assets and net operating losses (excluding the net operating losses pertaining to the liabilities assumed by the Company) followed the spin out. True Nature Holding, Inc. is not continuing the education software and systems business or utilizing any of the subsidiary’s assets going forward and therefore does not receive the tax benefit previously reported related to net operating losses that were created from debt not assumed.

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Note 11 - Commitments and Contingencies	Note 11 – Commitments and Contingencies Legal National Council for Science and the Environment, Inc. v. Trunity Holdings, Inc., Case No.. 2015 CA 009726 B, Superior Court for the District of Columbia, Civil Division On February 19, 2016, NCSE filed a motion to dismiss the counterclaim, and the Company has filed its brief in the opposition to that motion. A hearing is scheduled in second quarter 2016 on the motion. No discovery has been conducted by the parties yet, and no trial date has been set by the court. We have recorded a liability as of December 31, 2015 based on our best estimate of the probable exposure pertaining to the claim.

Note 12 - Financial Condition a

Note 12 - Financial Condition and Going Concern	12 Months Ended
	Dec. 31, 2015
Note 12 - Financial Condition And Going Concern
Note 12 - Financial Condition and Going Concern	Note 12 – Financial Condition and Going Concern As of December 31, 2015, the Company had cash on hand of $28,185 and liabilities of $564,873 and has incurred a loss from operations. True Nature Holding’s planned principal operations pertain to the business development and acquisition of pharmaceutical compounding companies. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company's continuance is dependent on raising capital and generating revenues sufficient to sustain operations. The Company believes that the necessary capital will be raised and has entered into discussions to do so with certain individuals and companies. However, as of the date of these consolidated financial statements, no formal agreement exists. The accompanying consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to secure the necessary capital and continue as a going concern.

Note 13 - Subsequent Events

Note 13 - Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Note 13 - Subsequent Events	Note 13 – Subsequent Events On April 4, 2016 the Company entered into a non-binding letter of intent to acquire Integrity Compounding Pharmacy in Dunwoody, Georgia, a suburb of Atlanta. The agreement calls for purchase consideration, approximating 12 months of revenue, and is estimated at $1 million. Consideration will be paid in a combination of the issuance of common stock, a convertible note that may convert into stock at a price not less than $1.25 per share, and a short term note payable. The final allocation of each of these will be determined prior to closing, which is expected to occur in second quarter 2016. Mr. Casey Gaetano, age 29, Founder and CEO, will join the management team at the Company at closing. On April 11, 2016 the Board of Directors elected Mr. James Driscoll, age 54, to the Board of Directors. Mr. Driscoll is currently CEO of Channel Terminals, LLC, a crude oil liquids terminals and refinery based in Houston, Texas. Mr. Driscoll is also a member of the Board of Directors at Double Zero Recycling LLC as well as an Advisory Board Member at HealPros LLC, a diabetic retinal imaging business, and Funding University LLC, an early stage online peer to peer lending business targeted on secondary education. Previously he was President of Method Holdings, LLC, from 2011 until late 2013. Between 2006 and 2011, Mr. Driscoll was a Senior Partner with private equity firm 1848 Capital Partners LLC. From 2009 to 2010, he was COO and Executive Vice President of CareDynamix LLC, a healthcare business focused on provision of onsite vaccination services around the US. In addition, Mr. Driscoll has over 14 years of experience at various senior positions in the power generation and transportation industries in varied locations around the world. He began his professional career as a trader in New York City. He has an MBA from Harvard University (1991) and a BA in English Literature from Bowdoin College (1984). On April 11, 2016, Dr. William Ross, age 70, advised the Company that he desired to resign from the Board of Directors, as he intends to retire from all business activities. There were no disagreements, or conflicts with the Board and Dr. Ross. During the first quarter of 2016, the Company raised gross proceeds of $60,000 through the sale of 120,000 shares of Common Stock to accredited investors in private placement transactions at a price of $0.50 per share. There were no issuance and commission costs incurred pertaining to the raise.

Note 2 - Summary of Significa20

Note 2 - Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting	Basis of Accounting
Use of Estimates	Use of Estimates -
Comprehensive Loss	Comprehensive Loss – Comprehensive income (loss) as defined includes all changes in equity during a period from non-owner sources. Items included in the Company’s comprehensive loss consist of unrealized gains (losses) on securities.
Cash	Cash -
Revenue Recognition	Revenue Recognition-
Stock-Based Compensation	Stock-Based Compensation- Equity instruments issued to other than employees are recorded on the basis of the fair value of the instruments. In general, the measurement date is when either a (a) performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant.
Convertible Instruments	Convertible Instruments-The Company reviews the terms of convertible debt and equity instruments to determine whether there are conversion features or embedded derivative instruments including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. In circumstances where the convertible instrument contains more than one embedded derivative instrument, including conversion options that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single compound instrument. Also, in connection with the sale of convertible debt and equity instruments, the Company may issue free standing warrants that may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity. When convertible debt or equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for separately, the total proceeds allocated to the convertible host instruments are first allocated to the fair value of the bifurcated derivative instrument. The remaining proceeds, if any, are then allocated to the convertible instruments themselves, usually resulting in those instruments being recorded at a discount from their face amount. When the Company issues debt securities, which bear interest at rates that are lower than market rates, the Company recognizes a discount, which is offset against the carrying value of the debt. Such discount from the face value of the debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to income. In addition, certain conversion features are recognized as beneficial conversion features to the extent the conversion price as defined in the convertible note is less than the closing stock price on the issuance of the convertible notes.
Common Stock Purchase Warrants	Common Stock Purchase Warrants-
Stockholders' Equity	Stockholders’ Equity-
Per Share Data	Per Share Data- The Company has excluded all common equivalent shares outstanding for warrants, options and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of December 31, 2015, the Company had 78,462 warrants, 67,879 options, 6,922 potential shares which may be issued resulting from the provisions of convertible notes, respectively. As of December 31, 2014, the Company had 171,369 warrants, 67,434 options, 168,869 potential shares which may be issued resulting from the provisions of convertible notes, respectively.
Income Taxes	Income Taxes- Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has determined that a valuation allowance is needed due to recent taxable net operating losses, the sale of profitable divisions and the limited taxable income in the carry back periods. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and certain tax loss carryforwards, less any valuation allowance. The Company accounts for uncertain tax positions as required in that a position taken or expected to be taken in a tax return is recognized in the consolidated financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company does not have any material unrecognized tax benefits. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as components of interest expense and other expense, respectively, in arriving at pretax income or loss. The Company does not have any interest and penalties accrued. The Company is generally no longer subject to U.S. federal, state, and local income tax examinations for the years before 2012.
Business Combinations	Business Combinations- ● future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and ● discount rates utilized in valuation estimates. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets-
Financial Instruments and Fair Values	Financial Instruments and Fair Values- Level 1 – inputs include exchange quoted prices for identical instruments and are the most observable. Level 2 – inputs include brokered and/or quoted prices for similar assets and observable inputs such as interest rates. Level 3 – inputs include data not observable in the market and reflect management judgment about the assumptions market participants would use in pricing the asset or liability. The use of observable and unobservable inputs and their significant in measuring fair value are reflected in our hierarchy assessment. The carrying amount of cash, prepaid assets, accounts payable and accrued liabilities approximates fair value due to the short-term maturities of these instruments. Because cash and cash equivalents are readily liquidated, management classifies these values as Level 1. The fair value of the debentures, approximate their book value as the instruments are short-term in nature and contain market rates of interest. Because there is no ready market or observable transactions, management classifies the debentures as Level 3.
Recently Issued Accounting Standards	Recently Issued Accounting Standards- In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, which relates to the financial statement presentation of debt issuance costs. This guidance requires debt issuance costs to be presented in the balance sheet as a reduction of the related debt liability rather than an asset. The guidance is effective for annual and interim periods beginning after December 15, 2015 and early adoption is permitted and will only result in a change in presentation of the costs on the balance sheet. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes. The guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. The guidance becomes effective for annual reporting periods beginning after December 15, 2016 with early adoption permitted. The adoption of this guidance will only result in a change in the presentation of deferred taxes on the balance sheet.

Note 4 - Spin-Out and Discont21

Note 4 - Spin-Out and Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Results of operations associated with discontinued operations	The results of operations associated with discontinued operations were as follows: For the Year Ended December 31, December 31, 2015 2014 Net Sales $ 464,786 $ 227,655 Cost of sales 220,228 172,966 Gross Profit 244,558 54,689 Operating Expenses: Research and development 734,985 892,092 Selling, general and administrative 938,799 2,235,012 Total operating expenses 1,673,784 3,127,104 Operating Loss from Discontinued Operations (1,429,226 ) (3,072,415 ) Other Expense: Interest expense, net (775,564 ) (381,941 ) Disposal on fixed assets — (5,692 ) Gain (Loss) on debt extinguishment 1,867,428 (310,096 ) Net Loss from Discontinued Operations $ (337,362 ) $ (3,770,144 ) Other Comprehensive Gain Net of Tax: Foreign currency translation adjustments 24,815 14,325 Comprehensive Loss from Discontinued Operations $ (312,547 ) $ (3,755,819 )
Carrying value of the major categories of assets and liabilities of discontinued operations	The following table presents the carrying value of the major categories of assets and liabilities of discontinued operations reflected on the Company’s consolidated balance sheet as of December 31, 2014: 2014 Cash and cash equivalents $ 14,119 Accounts receivable 3,020 Prepaid expenses and other current assets 104,592 Debt issuance costs 35,899 Property and equipment, net 19,716 Capitalized software development costs, net 774,406 Other assets 12,895 ASSETS OF DISCONTINUED OPERATIONS $ 964,647 Accounts payable $ 984,841 Accrued interest and other liabilities 300,297 Debentures carrying value 1,334,996 Convertible note payable 115,463 Deferred revenue 324,169 Convertible promissory notes 45,089 TOTAL LIABILITIES $ 3,104,855

Note 8 - Stock-Based Compensa22

Note 8 - Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of options issued, exercised and cancelled	A summary of options issued, exercised and cancelled are as follows: Shares Weighted- Average Exercise Price ($) Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value ($) Outstanding at December 31, 2013 82,336 $ 42,42 9.09 — Granted 13,159 21.21 9.11 — Cancelled (28,061 ) 46.46 — — Outstanding at December 31, 2014 67,434 $ 26.26 8.11 — Granted 1,683 2.08 9.18 — Cancelled (1,238 ) 18.79 — — Outstanding at December 31, 2015 67,879 $ 21.40 7.17 — Exercisable at December 31, 2015 66,270 $ 36.70 6.79 —

Note 9 - Warrants to Purchase23

Note 9 - Warrants to Purchase Common Stock (Tables)	12 Months Ended
	Dec. 31, 2015
Note 9 - Warrants To Purchase Common Stock
Summary of warrants issued, exercised and expired	A summary of warrants issued, exercised and expired are as follows: Shares Weighted- Average Exercise Price ($) Weighted-Average Remaining Contractual Term Outstanding at December 31, 2013 103,823 $ 101 1.36 Granted 70,753 29.29 4.41 Expired (3,207 ) 303 — Outstanding at December 31, 2014 171,369 $ 70.70 2.04 Granted 5,233 16.36 2.67 Expired (98,140 ) 100.81 — Outstanding at December 31, 2015 78,462 $ 29.55 3.43 Exercisable at December 31, 2015 78,462 $ 29.55 3.43

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Company's net deferred tax assets and liabilities	As of December 31, 2015 Tax Deferred Asset: Net operating loss carryforward $ 238,784 Deferred Tax Assets $ 238,784 Valuation Allowance (238,784 ) Total Net Deferred Tax Asset $ —

Note 1 - Organization, Basis 25

Note 1 - Organization, Basis of Presentation and Nature of Operations (Details Narrative) - shares	Dec. 09, 2015	Dec. 18, 2015	Dec. 31, 2015	Dec. 31, 2014
Reverse spilit		1 for 101
Common stock shares authorized		500,000,000	500,000,000	1,980,198
Preferred stock shares authorized		100,000,000	10,000,000	50,000,000
Shares outstanding			11,765,000
Legacy shareholders [Member]
Shares outstanding			1,765,000
N4P [Member]
Percentage of Business Acquired	100.00%		100.00%
Conversion of Series X preferred stock to common stock	10,000,000		10,000,000
Shares outstanding			10,000,000

Note 2 - Summary of Significa26

Note 2 - Summary of Significant Accounting Policies (Details Narrative) - shares	1 Months Ended		12 Months Ended
	Jan. 31, 2016	Dec. 18, 2015	Dec. 31, 2015	Dec. 31, 2014
Reverse spilit		1 for 101
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			78,462	171,369
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			67,879	67,434
Convertible Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			6,922	168,869
Subsequent Event [Member]
Reverse spilit	1 for 101

Note 3 - Newco4pharmacy Trans27

Note 3 - Newco4pharmacy Transaction (Details Narrative) - USD ($)	Dec. 09, 2015	Dec. 31, 2015	Dec. 31, 2014
Conversion of Series X preferred stock to common stock, value			$ 24,750
N4P [Member]
Percentage of Business Acquired	100.00%	100.00%
Conversion of Series X preferred stock to common stock	10,000,000	10,000,000
Conversion of Series X preferred stock to common stock, value	$ 106,900	$ 106,900

Note 4 - Spin-Out and Discont28

Note 4 - Spin-Out and Discontinued Operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Other Expense:
Gain (Loss) on debt extinguishment		$ 310,096
Net Loss from Discontinued Operations	$ (337,362)	(3,770,144)
Other Comprehensive Gain Net of Tax:
Comprehensive Loss from Discontinued Operations	(312,547)	(3,755,819)
Trunity Holdings, Inc. [Member]
Net Sales	464,786	227,655
Cost of sales	220,228	172,966
Gross Profit	244,558	54,689
Operating expenses:
Research and development	734,985	892,092
Selling, general and administrative	938,799	2,235,012
Total operating expenses	1,673,784	3,127,104
Operating Loss from Discontinued Operations	(1,429,226)	(3,072,415)
Other Expense:
Interest expense, net	$ (775,564)	(381,941)
Disposal on fixed assets		(5,692)
Gain (Loss) on debt extinguishment	$ 1,867,428	(310,096)
Net Loss from Discontinued Operations	(337,362)	(3,770,144)
Other Comprehensive Gain Net of Tax:
Foreign currency translation adjustments	24,815	14,325
Comprehensive Loss from Discontinued Operations	$ (312,547)	$ (3,755,819)

Note 4 - Spin-Out and Discont29

Note 4 - Spin-Out and Discontinued Operations (Details 1) - Trunity Holdings, Inc. [Member]	Dec. 31, 2014USD ($)
Cash and cash equivalents	$ 14,119
Accounts receivable	3,020
Prepaid expenses and other current assets	104,592
Debt issuance costs	35,899
Property and equipment, net	19,716
Capitalized software development costs, net	774,406
Other assets	12,895
ASSETS OF DISCONTINUED OPERATIONS	964,647
Accounts payable	984,841
Accrued interest and other liabilities	300,297
Debentures carrying value	1,334,996
Convertible note payable	115,463
Deferred revenue	324,169
Convertible promissory notes	45,089
TOTAL LIABILITIES	$ 3,104,855

Note 5 - Related Party Transa30

Note 5 - Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Prepaid expenses - related party	$ 17,000
Stephen Keaveney [Member]
Accrued Professional fees	10,000
Professional fees per month paid	10,000
Shareholder [Member]
Accrued Professional fees	10,000
Professional fees per month paid	$ 27,000
Board member [Member]
Shares purchased	40,000
Shares purchased, price per share	$ 0.13
Shares purchased, value	$ 5,000

Note 6 - Debt (Details Narrativ

Note 6 - Debt (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
November 2014 Convertible Debentures (Series D) [Member]
Convertible Debentures, Face Value	$ 10,000
Interest rate	12.00%
Maturity date	Oct. 31, 2015
Debt instrument conversion price	$ 16.67
Warrants to purchase of common stock	495
Warrants to purchase of common stock exercise price	$ 20.20
Warrants to purchase of common stock term	5 years
Convertible Debentures, Carrying Value	$ 11,334	$ 11,334
Accrued Interest	1,581	224
November 2014 Convertible Debentures (Series B) [Member]
Convertible Debentures, Face Value	11,334
August 2014 Convertible Debentures (Series C) [Member]
Convertible Debentures, Face Value	$ 100,000
Interest rate	10.00%
Maturity date	Oct. 31, 2015
Debt instrument conversion price	$ 20.20
Warrants to purchase of common stock	4,950
Warrants to purchase of common stock exercise price	$ 20.20
Warrants to purchase of common stock term	5 years
Convertible Debentures, Carrying Value	$ 110,833	110,833
Accrued Interest	13,337	$ 1,847
August 2014 Convertible Debentures (Series B) [Member]
Convertible Debentures, Face Value	$ 110,833

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit (Details Narrative) - USD ($)	Dec. 09, 2015	Dec. 31, 2015	Dec. 31, 2014
Conversion of Series X preferred stock to common stock, value			$ 24,750
Shares outstanding		11,765,000
N4P [Member]
Percentage of Business Acquired	100.00%	100.00%
Conversion of Series X preferred stock to common stock	10,000,000	10,000,000
Conversion of Series X preferred stock to common stock, value	$ 106,900	$ 106,900
Shares outstanding		10,000,000
Legacy shareholders [Member]
Shares outstanding		1,765,000
Stephen Keaveney [Member]
Shares issued		3,488,900
Various individuals [Member]
Shares issued		5,797,100

Note 8 - Stock-Based Compensa33

Note 8 - Stock-Based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options Outstanding	67,434	82,336
Option Granted	1,683	13,159
Option Cancelled	(1,238)	(28,061)
Options Outstanding	67,879	67,434
Options exercisable at End	66,270
Outstanding at Beginning, Weighted-Average Exercise Price	$ 26.26	$ 42.42
Weighted- Average Exercise Price, Granted	2.08	21.21
Weighted- Average Exercise Price, Cancelled	18.79	46.46
Outstanding at Ending, Weighted-Average Exercise Price	21.40	$ 26.26
Weighted- Average exercisable at End	$ 36.70
Weighted- Average Remaining Contractual Term, Beginning balance	8 years 1 month 10 days	9 years 1 month 2 days
Weighted- Average Remaining Contractual Term, Granted	9 years 2 months 5 days	9 years 1 month 10 days
Weighted- Average Remaining Contractual Term, Ending Balance	7 years 2 months 1 day	8 years 1 month 10 days
Weighted- Average Remaining Contractual Term, exercisable at End	6 years 9 months 15 days
Aggregate Intrinsic Value	$ 0	$ 0
Aggregate Intrinsic Value, exercisable at End	$ 0

Note 8 - Stock-Based Compensa34

Note 8 - Stock-Based Compensation (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 18, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Reverse spilit	1 for 101
Options Outstanding		67,879	67,434	82,336
Weighted average grant-date fair value of stock options granted		$ 2.08
Dividend Rate		0.00%
Unrecognized stock compensation expense		$ 12,550
Unrecognized stock compensation expense recognition period		1 year
Share based compensation		$ 3,917
Chief Executive Officer [Member]
Options Outstanding		24,753
Employee, Director and Consultant
Number of option granted		1,683
2012 Employee, Director and Consultant Stock Option Plan (the "2012 Plan")
Authorized option pool		74,257
Shares available for awards		45,673
Reverse spilit		1 for 101
Stock option description		Stock options typically vest over a three year period and have a life of ten years from the date granted.
2009 Employee, Director and Consultant Stock Option Plan (the " 2009 Plan")
Authorized option pool		18,152
Shares available for awards		3,610
Reverse spilit		1 for 101
Stock option description		Stock options typically vest over a three-year period and have a life of ten years from the date granted.
Minimum [Member]
Risk Free Interest Rate		1.60%
Expected Volatility		44.90%
Expected Term		6 years
Maximum [Member]
Risk Free Interest Rate		2.20%
Expected Volatility		50.10%
Expected Term		10 years

Note 9 - Warrants to Purchase35

Note 9 - Warrants to Purchase Common Stock (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Options Outstanding	67,434	82,336
Options Granted	1,683	13,159
Options Expired	(1,238)	(28,061)
Options Outstanding	67,879	67,434
Options exercisable at End	66,270
Outstanding at Beginning, Weighted-Average Exercise Price	$ 26.26	$ 42.42
Weighted- Average Exercise Price, Granted	2.08	21.21
Weighted- Average Exercise Price, Expired	18.79	46.46
Outstanding at Ending, Weighted-Average Exercise Price	21.40	$ 26.26
Weighted- Average exercisable at End	$ 36.70
Weighted- Average Remaining Contractual Term, Beginning balance	8 years 1 month 10 days	9 years 1 month 2 days
Weighted- Average Remaining Contractual Term, Granted	9 years 2 months 5 days	9 years 1 month 10 days
Weighted- Average Remaining Contractual Term, Ending Balance	7 years 2 months 1 day	8 years 1 month 10 days
Weighted- Average Remaining Contractual Term, exercisable at End	6 years 9 months 15 days
Warrant [Member]
Options Outstanding	171,369	103,823
Options Granted	5,233	70,753
Options Expired	(98,140)	(3,207)
Options Outstanding	78,462	171,369
Options exercisable at End	78,462
Outstanding at Beginning, Weighted-Average Exercise Price	$ 70.70	$ 101
Weighted- Average Exercise Price, Granted	16.36	29.29
Weighted- Average Exercise Price, Expired	100.81	303
Outstanding at Ending, Weighted-Average Exercise Price	29.55	$ 70.70
Weighted- Average exercisable at End	$ 29.55
Weighted- Average Remaining Contractual Term, Beginning balance	2 years 15 days	1 year 4 months 10 days
Weighted- Average Remaining Contractual Term, Granted	2 years 8 months 1 day	4 years 4 months 28 days
Weighted- Average Remaining Contractual Term, Ending Balance	3 years 5 months 5 days	2 years 15 days
Weighted- Average Remaining Contractual Term, exercisable at End	3 years 5 months 5 days

Note 9 - Warrants to Purchase36

Note 9 - Warrants to Purchase Common Stock (Details Narrative) - $ / shares	1 Months Ended	12 Months Ended
	Dec. 18, 2015	Dec. 31, 2015
Reverse spilit	1 for 101
Warrant [Member]
Reverse spilit		1 for 101
Warrants issued to purchase shares		5,233
Warrants expires through		Dec. 31, 2019
Warrant [Member] | Minimum [Member]
Exercise Price		$ 15.15
Warrant [Member] | Maximum [Member]
Exercise Price		$ 90.90

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details)	Dec. 31, 2015USD ($)
Tax Deferred Asset:
Net operating loss carryforward	$ 238,784
Deferred Tax Assets	238,784
Valuation Allowance	$ (238,784)
Total Net Deferred Tax Asset

Note 10 - Income Taxes (Detai38

Note 10 - Income Taxes (Details Narrative)	12 Months Ended
	Dec. 31, 2015USD ($)
Net deferred tax assets	$ 629,042
Deferred Tax Assets	238,784
Federal operating losses carried forward	$ 629,042
Federal operating losses carried forward, expiration date	Dec. 31, 2036
Newco4pharmacy, LLC [Member]
Net deferred tax assets	$ 15,500,000
Deferred Tax Assets	$ 6,100,000

Note 11 - Commitments and Con39

Note 11 - Commitments and Contingencies (Details Narrative)	1 Months Ended
	Dec. 16, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
Damages sought	$ 177,270
Interest rate	12.00%

Note 12 - Financial Condition40

Note 12 - Financial Condition and Going Concern (Details Narrative) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Note 12 - Financial Condition And Going Concern
Cash on hand	$ 28,185
Liabilities	$ 564,873	$ 3,229,093

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)	3 Months Ended
	Mar. 31, 2016	Apr. 04, 2016
Agreement purchase consideration		$ 1,000,000
Debt instrument conversion price		$ 1.25
Proceeds from private placement	$ 60,000
Proceeds from private placement, shares	120,000
Proceeds from private placement, price per share	$ 0.50